Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | Highlights at COSTEM 2022

Sergio Giralt • 29 Oct 2022
COSTEM 2022
Lymphoma Multiple Myeloma Antibodies CAR-T

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides his highlights from the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), including discussions comparing CAR-T therapy with bispecific T-cell engagers (BiTEs) in multiple myeloma, as well as CAR-Ts with transplantation in myeloma and lymphoma. Dr Giralt additionally mentions debates relating to measuring MRD positivity before or after transplantation. This interview took place at COSTEM 2022 in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Sergio Giralt

1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023
0:59
The role of radioimmunoconjugates in AML treatment: insights from the SIERRA trial
Sergio Giralt • 8 Dec 2023
2:03
The evolving role of transplantation in multiple myeloma in the age of novel immunotherapeutics
Sergio Giralt • 8 Dec 2023
1:29
Final results of KarMMa-3: ide-cel in R/R MM
Sergio Giralt • 8 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The content of VJHemOnc is intended for healthcare professionals